Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Assets (2020 - 2025)

Gain Therapeutics has reported Assets over the past 6 years, most recently at $11.0 million for Q3 2025.

  • Quarterly results put Assets at $11.0 million for Q3 2025, down 23.63% from a year ago — trailing twelve months through Sep 2025 was $11.0 million (down 23.63% YoY), and the annual figure for FY2024 was $12.1 million, down 34.85%.
  • Assets for Q3 2025 was $11.0 million at Gain Therapeutics, up from $9.8 million in the prior quarter.
  • Over the last five years, Assets for GANX hit a ceiling of $48.0 million in Q1 2021 and a floor of $9.8 million in Q2 2025.
  • Median Assets over the past 5 years was $19.2 million (2024), compared with a mean of $24.3 million.
  • Biggest five-year swings in Assets: surged 305.91% in 2021 and later tumbled 50.23% in 2023.
  • Gain Therapeutics' Assets stood at $39.0 million in 2021, then crashed by 38.18% to $24.1 million in 2022, then dropped by 22.78% to $18.6 million in 2023, then crashed by 34.85% to $12.1 million in 2024, then decreased by 9.5% to $11.0 million in 2025.
  • The last three reported values for Assets were $11.0 million (Q3 2025), $9.8 million (Q2 2025), and $11.6 million (Q1 2025) per Business Quant data.